KACTUS at SITC 2024
We are thrilled to announce our participation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting, held in Houston, TX from November 8-10, 2024. This premier event is dedicated to advancing cancer immunotherapy, featuring in-depth sessions on groundbreaking topics like B-cell function, the microbiome's role in cancer therapy, and cellular treatments. With a diverse gathering of researchers, clinicians, and industry leaders, SITC offers an unparalleled opportunity to explore the future of immunotherapy and drive collaboration within the field.
What is SITC?
The Society for Immunotherapy of Cancer (SITC) is a professional organization dedicated to advancing the science and application of cancer immunotherapy. It provides a platform for researchers, clinicians, and industry professionals to share knowledge, collaborate, and promote innovative treatments to improve cancer patient outcomes. SITC's annual meeting is one of the largest gatherings in the field, showcasing the latest research and developments in cancer immunotherapy.
Event Overview
Venue: George R. Brown Convention Center 1001 Avenida De Las Americas, Houston, TX 77010
Dates: November 8th to 10th, 2024
- Conference Day 1: Friday 08 November, 2024 8:00am - 7:00pm
- Conference Day 2: Saturday 09 November, 2024 8:00am - 8:30pm
- Conference Day 3: Sunday 10 November, 2024 8:00am - 12:30pm
KACTUS Booth Number 819
Event Schedule
The SITC 2024 Annual Meeting includes a variety of sessions, workshops, and keynote addresses. Topics cover areas like cancer immunotherapy, B-cell function, the role of the microbiome, and cellular treatments. The event kicks off with pre-conference programs on November 6-7, and also features dedicated activities for early career scientists. For the full conference schedule, you can visit the SITC agenda webpage.
Day 1 November 8th 2024
- Presidential Welcome at 7:45-7:50 AM
- Remembrance of Dr. Jeffrey Weber at 7:50-7:55 AM
- Awards Ceremony 1 at 7:55-8:20 AM
- Keynote Address at 8:20-9:10 AM
- Exhibit Hall Open from 9:00am to 7:00pm
- Break at 9:10-9:40 AM
- Session 103: Pre-malignancy Biology at 9:40-11:45 AM
- Session 104: Late-Breaking Abstracts at 11:45 AM-12:15 PM
- Lunch and Poster Viewing at 12:15-1:45 PM
- Session 105a: Rapid Oral Abstracts - Basic at 12:30-1:30 PM
- Session 105b: Rapid Oral Abstracts - Clinical at 12:30-1:30 PM
- Concurrent Sessions 106a-106e (covering topics like B Cells, Microbiome, NK Cells, and more) at 1:45-3:20 PM
- Break at 3:20-3:50 PM
- Concurrent Sessions 107a-107f (covering Cellular Therapies, Protein Engineering, Immune Exclusion, and more) at 3:50-5:25 PM
- Poster Reception at 5:30-7:00 PM
Day 2 November 9th 2024
- Organizer Welcome at 8:00-8:05 AM
- Richard V. Smalley Award and Lectureship at 8:05-8:55 AM
- Exhibit Hall Open from 9:00am to 8:30pm
- Session 203: Genomic Instability at 8:55-11:00 AM
- Break at 11:00-11:15 AM
- Fireside Chat at 11:15-11:45 AM
- Session 204: Late-Breaking Abstracts at 11:45 AM-12:15 PM
- Lunch and Poster Viewing at 12:15-1:45 PM
- Sessions: Rapid Oral Abstracts - Basic (205a) and Clinical (205b) at 12:30-1:30 PM
- Presidential Session at 1:45-3:10 PM
- Break at 3:10-3:25 PM
- Concurrent Sessions 207a-207e (covering topics like CD4 & Tregs, Biomarkers, Modulating Tumor Vasculature, and more) at 3:25-4:45 PM
- Break at 4:45-5:15 PM
- Concurrent Sessions 208a-208e (covering Myeloid Cells, Cellular Therapies, Biomarkers, and more) at 5:15-6:35 PM
- Awards Ceremony at 6:40-7:10 PM
- Poster Reception at 7:10-8:30 PM
- The CheckPoints Party at 8:30 PM-Midnight
Day 3 November 10th 2024
- Organizer Welcome at 8:15-8:20 AM
- Session 301: Thomas Waldmann Memorial Plenary Session – Understanding Response and Resistance at 8:20-10:30 AM
- Break at 10:30-11:00 AM
- Session 302: Hot Topic Symposium – AI in Discovery at 11:00 AM-12:35 PM
Featured KACTUS Products
Why Choose KACTUS?
About KACTUS
KACTUS excels in crafting and producing an array of superior-grade, highly active recombinant proteins and enzymes, catering to diverse sectors like antibody drug discovery, immunotherapy, gene therapy, and mRNA therapeutics. Our expansive catalog, boasting over 2500 recombinant proteins, encompasses a wide spectrum of targets, species, tags, and labels, each thoughtfully chosen to address the specific, unmet needs of scientists engaged in drug development. The hallmark of our product selection process is a rigorous emphasis on exceptional quality and a steadfast commitment to ensuring reliable supply, thereby upholding the highest standards of excellence and client satisfaction.